Visiting The Royal Marsden is suspended

Coronavirus latest: Please kindly note that whilst lockdown restrictions are beginning to ease, visiting is still suspended.  The hospital remains open and we are still delivering treatment to our patients. Please see more information here about how we are keeping everyone safe.

Professor Stephen Johnston

Professor of Breast Cancer Medicine and Consultant Medical Oncologist MA PhD FRCP

Specialism: Breast

Available at: Chelsea, Sutton

Special interests:

  • medical treatment of breast cancer
  • adjuvant chemotherapy for early breast cancer
  • endocrine therapies
  • treatment of advanced/metastatic breast cancer
  • novel targeted therapies


Stephen Johnston is Professor of Breast Cancer Medicine and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London. He took up his position at The Royal Marsden in 1997 and was the first Director of the National Institute for Health Research (NIHR) Biomedical Research Centre at The Royal Marsden from 2007 to 2012. He is currently Head of Medical Oncology, and also the Head of the Breast Unit.

He graduated in 1983 from Trinity College at the Cambridge University, and in 1986 from the Medical School at the University of Newcastle-upon- Tyne. He trained in general medicine at St Bartholomew's Hospital and Hammersmith Hospital in London, and subsequently in medical oncology at The Royal Marsden. He gained his PhD from The Institute of Cancer Research at the University of London, and took up his current position as Consultant Medical Oncologist in the Breast Unit at The Royal Marsden in 1997.

He has a specialist interest in the treatment of hormone receptor positive breast cancer, and my major research interests lie in understanding mechanisms of endocrine resistance in breast cancer. He is actively involved in facilitating the interface between basic and applied research and am the chief investigator of several international phase III trials of novel therapeutic approaches including new endocrine therapies and targeted therapies for hormone receptor positive breast cancer.

He has published over 280 breast cancer related articles in peer-reviewed journals and is a regular invited lecturer at national and international meetings. He is a member of several scientific committees and advisory boards, a prior Faculty member at the American Society for Clinical Oncology and a current member of San Antonio Breast Cancer Symposium abstract review committee.

Clinical units